Regístrese
covid
Revista Colombiana de Cancerología
Buscar en
Revista Colombiana de Cancerología
Toda la web
Inicio Revista Colombiana de Cancerología Ganglio centinela en melanoma maligno cutáneo de tronco y extremidades. Experie...
Información de la revista
Artículo anterior | Artículo siguiente
Vol. 15. Núm. 3.
Páginas 119-126 (enero 2010)
Exportar referencia
Compartir
Compartir
Imprimir
Descargar PDF
Más opciones de artículo
Estadísticas
Vol. 15. Núm. 3.
Páginas 119-126 (enero 2010)
DOI: 10.1016/S0123-9015(11)70060-9
Acceso a texto completo
Ganglio centinela en melanoma maligno cutáneo de tronco y extremidades. Experiencia en el Instituto Nacional de Cancerología, Bogotá, Colombia, 2000–2007
Sentinel Node in Cutaneous Malignant Melanoma in the Trunk and Extremities: Experience at the National Cancer Institute, Bogotá, Colombia, 2000–2007
Visitas
3113
Descargar PDF
Óscar García1,
Autor para correspondencia
osaga72@gmail.com

Correspondencia: Instituto Nacional de Cancerología. Consulta de Seno y Tejidos Blandos. Avenida 1a No. 9-85. Bogotá, Colombia. Tel.: (571) 3341111 Ext. 5424.
, Édgar Vergara1, Carlos Duarte1, Licet Villamizar2, Sandra Díaz1, Fernando Perry1, Javier Ángel1
1 Grupo de Cirugía de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
2 Grupo de Investigación Clínica, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
Este artículo ha recibido
3113 Visitas
Información del artículo
Estadísticas
Resumen
Objetivo

Determinar la tasa de recurrencia regional en pacientes diagnosticados con melanoma maligno cutáneo localizado en tronco y extremidades, con una biopsia de ganglio centinela negativa.

Métodos

Serie de casos. Se revisaron los registros de pacientes estadio clínico IB, IIA, IIB, IIIC tratados con biopsia de ganglio centinela entre enero de 2000 y diciembre de 2007. Se realizaron análisis descriptivos y se analizó la supervivencia mediante el método de Kaplan-Meier.

Resultados

Se incluyó a 170 pacientes. La mediana de seguimiento fue de 21,5 meses, con una tasa de recurrencia regional del 11,76%. La supervivencia global a 24 meses en ganglio centinela negativo fue del 100%.

Conclusiones

La tasa de recurrencia regional en la serie analizada de pacientes con melanoma y ganglio linfático centinela negativo se halla dentro de lo reportado en la literatura, aunque el tiempo de seguimiento es relativamente corto.

Palabras clave:
Melanoma
biopsia del ganglio linfático centinela
supervivencia sin enfermedad
mortalidad global
Abstract
Objective

To determine the regional recurrence rate in patients diagnosed with cutaneous malignant melanoma in the trunk and extremities, and with negative sentinel node biopsy.

Methods

A case series was utilized to review patients with clinical registries IB, IIA, IIB, IIIC treated with sentinel node biopsy between January, 2000 and December, 2007. Descriptive analysis was performed and survival analysis carried out with the Kaplan-Meier method.

Results

The study included 170 patients. Median follow-up was 21.5 months, with regional recurrence rate at 11.76%. Overall survival rate at 24 months for negative sentinel node was 100%.

Conclusions

The regional recurrence rate in the series analyzed of patients with melanoma and negative sentinel lymph node is situated within that reported in the literature; however, follow up is relatively short.

Key words:
Melanoma
Sentinel Lymph Node Biopsy
Disease-free Survival
Mortality
El Texto completo está disponible en PDF
Referencias
[1.]
A. Jemal, R. Siegel, E. Ward, et al.
Cancer statistics, 2007.
CA Cancer J Clin, 57 (2007), pp. 43-66
Medline
[2.]
República de, Colombia, Instituto Nacional de Cancerología (INC).
Registro institucional de cáncer: anuario estadístico 2006.
INC, (2007),
[3.]
República de, Colombia, Instituto Nacional de Cancerología (INC).
Registro institucional de cáncer: anuario estadístico 2007.
INC, (2008),
[4.]
República de, Colombia, Instituto Nacional de Cancerología (INC).
Registro institucional de cáncer: anuario estadístico 2008.
INC, (2009),
[5.]
C. Balch, S. Soong, J.E. Gershenwald, et al.
Prognostic factor analysis of 17600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.
J Clin Oncol, 19 (2001), pp. 3622-3634
http://dx.doi.org/10.1200/jco.2001.19.16.3622 | Medline
[6.]
G.W. Milton, H.H. Shaw, W.J. Mc Carthy, et al.
Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients.
Br J Surg, 69 (1982), pp. 108-111
Medline
[7.]
F.H. Sim, W.F. Taylor, J.C. Ivins, et al.
A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma.
Cancer, 41 (1978), pp. 948-956
Medline
[8.]
U. Veronesi, J. Adamus, D.C. Bandiera, et al.
Inefficacy of immediate node dissection of stage I melanoma of the limbs.
N Eng J Med, 297 (1977), pp. 627-630
[9.]
U. Veronesi, J. Adamus, D.C. Bandiera, et al.
Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities.
Cancer, 49 (1982), pp. 2420-2430
Medline
[10.]
D.L. Morton, L. Wanek, J. Nizze, et al.
Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic.
Ann Surg., 214 (1991), pp. 491-501
Medline
[11.]
F.H. Sim, W.F. Taylor, D.J. Pritchard, et al.
Lymphadenectomy in the management of stage I malignant melanoma: A prospective randomized study.
Mayo Clin Proc, 61 (1986), pp. 697-705
Medline
[12.]
N. Cascinelli, A. Morabito, M. Santinami, et al.
Inmediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomized trial. WHO Melanoma Programme.
Lancet, 351 (1998), pp. 793-796
Medline
[13.]
D.M. Balch, S. Soong, M.I. Ross, et al.
Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanoma (1.0 to 4.0mm). Intergroup Melanoma Surgical Trial.
Ann Surg Oncol, 7 (2000), pp. 87-97
Medline
[14.]
D.L. Morton, J.F. Thompson, A.J. Cochran, et al.
Sentinelnode biopsy or nodal observation in melanoma.
N Engl J Med, 355 (2006), pp. 1307-1317
http://dx.doi.org/10.1056/NEJMoa060992 | Medline
[15.]
D.L. Morton, A.J. Cochran.
The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma.
Br J Dermatol, 151 (2004), pp. 308-319
http://dx.doi.org/10.1111/j.1365-2133.2004.06133.x | Medline
[16.]
D.L. Morton.
Sentinel lymphadenectomy for patients with clinical stage I melanoma.
J Surg Oncol, 66 (1997), pp. 267-269
Medline
[17.]
A. Piris, M.C. Mihm.
Progress in melanoma histopathology and diagnosis.
Hematol Oncol Clin N Am, 23 (2009), pp. 467-480
[18.]
C.M. Balch, S. Soong, M.B. Atkins, et al.
An evidence-based staging system for cutaneous melanoma.
CA Cancer J Clin, 54 (2004), pp. 131-149
Medline
[19.]
K.M. McMasters, R.D. Noyes, D.S. Reintgen, et al.
Lessons learned from the Sunbelt Melanoma Trial.
J Surg Oncol, 86 (2004), pp. 212-223
http://dx.doi.org/10.1002/jso.20084 | Medline
[20.]
República de, Colombia, Instituto Nacional de Cancerología (INC).
Melanoma: guía de práctica clínica en enfermedades neoplásicas.
INC, (2001),
[21.]
W. Seaman, W.E. Powers.
Studies on the distribution of radioactive colloidal gold in regional lymph nodes containing cancer.
Cancer, 8 (1995), pp. 1044-1046
Medline
[22.]
E.A. Gould, T. Winship, P.H. Philbin, et al.
Observations on a sentinel node in cancer of the parotid.
Cancer, 13 (1960), pp. 77-78
http://dx.doi.org/10.1186/1471-2407-13-77 | Medline
[23.]
R.M. Cabañas.
An approach for the treatment of penile carcinoma.
Cancer, 39 (1977), pp. 456-466
Medline
[24.]
J.F. Thompson, P. Niewind, R.F. Uren, et al.
Single-dose isotope injection for both preoperative lymphoscintigraphy and intraoperative sentinel lymph node identification in melanoma patients.
Melanoma Res, 7 (1997), pp. 500-506
Medline
[25.]
D.L. Rousseau Jr., M.I. Ross, M.M. Johnson, et al.
Revised American Joint Committee on Cancer stanging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients.
Ann Surg Oncol, 10 (2003), pp. 569-574
Medline
[26.]
J.H. Lee, R. Essner, H. Torisu-Itakura, et al.
Factors predictive of tumor-positive nonsentinel lymph nodes after tumorpositive sentinel lymph node dissection for melanoma.
J Clin Oncol, 22 (2004), pp. 3677-3684
http://dx.doi.org/10.1200/JCO.2004.01.012 | Medline
[27.]
A.J. Cochran, D.R. Wen, R.R. Huang, et al.
Prediction of metastatic melanoma in nonsentinel nodes and clinical outcomes based on the primary melanoma and the sentinel node.
Mod Pathol, 17 (2004), pp. 747-755
http://dx.doi.org/10.1038/modpathol.3800117 | Medline
[28.]
D. Morton, A. Cochran, J. Thompson, et al.
Sentinel Node Biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an International Multicenter Trial.
Ann Surg, 242 (2005), pp. 302-313
Medline
[29.]
S.P. Hettiaratchy, N. Kange, G. O’Tootle, et al.
Sentinel lymph node biopsy in malignant melanoma: a series of 100 consecutive patients.
Br J Plast Surg, 53 (2000), pp. 559-662
http://dx.doi.org/10.1054/bjps.2000.3409 | Medline
[30.]
M.S. Sabel, K.A. Griffith, A. Arora, et al.
Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy.
Surgery, 141 (2007), pp. 728-735
http://dx.doi.org/10.1016/j.surg.2006.12.018 | Medline
[31.]
D. Morton, A. Cochran, J. Thompson, R. Elashoff, R. Essner, E.C. Glass, et al.
Sentinel Node Biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an International Multicenter Trial.
Ann Surg, 242 (2005), pp. 302-313
Medline
[32.]
M.G. Rughani, M.C. Swan, T.S. Adams, M.R. Middleton, R.N. Ramcharan, A. Pay, et al.
Sentinel lymph node biopsy in melanoma: the Oxford ten year clinical experience.
J Plast Reconstr Aesthet Surg, 64 (2011), pp. 1284-1290
http://dx.doi.org/10.1016/j.bjps.2011.05.001 | Medline
[33.]
I. Satzger, A. Meier, L. Hoy, B. Völker, A. Kapp, A. Hauschild, et al.
Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up.
Ann Surg Oncol, 18 (2011), pp. 514-520
http://dx.doi.org/10.1245/s10434-010-1318-3 | Medline
[34.]
C.M. Balch, S. Soong, M.I. Ross, M.M. Urist, C.P. Karakousis, W.J. Temple, et al.
Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0mm). Intergroup Melanoma Surgical Trial.
Ann Surg Oncol, 7 (2000), pp. 87-97
Medline
[35.]
N. Cascinelli, F. Belli, M. Santinami, et al.
Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience.
Ann Surg Oncol, 7 (2000), pp. 469-474
Medline
Copyright © 2011. Instituto Nacional de Cancerología

Suscríbase a la newsletter

Revista Colombiana de Cancerología se adhiere a los principios y procedimientos dictados por el Committee on Publication Ethics (COPE)
www.publicationethics.org.
Descargar PDF
Opciones de artículo